APA (7th ed.) Citation

E, C. A., M, Y. S., F, T. A., & T, A. D. (2022). Ciltacabtagene autoleucel: The second anti-BCMA CAR T-cell therapeutic armamentarium of relapsed or refractory multiple myeloma. Frontiers in immunology, 13, 991092. https://doi.org/10.3389/fimmu.2022.991092

Chicago Style (17th ed.) Citation

E, Chekol Abebe, Yibeltal Shiferaw M, Tadele Admasu F, and Asmamaw Dejenie T. "Ciltacabtagene Autoleucel: The Second Anti-BCMA CAR T-cell Therapeutic Armamentarium of Relapsed or Refractory Multiple Myeloma." Frontiers in Immunology 13 (2022): 991092. https://doi.org/10.3389/fimmu.2022.991092.

MLA (9th ed.) Citation

E, Chekol Abebe, et al. "Ciltacabtagene Autoleucel: The Second Anti-BCMA CAR T-cell Therapeutic Armamentarium of Relapsed or Refractory Multiple Myeloma." Frontiers in Immunology, vol. 13, 2022, p. 991092, https://doi.org/10.3389/fimmu.2022.991092.